Ligand is a biopharmaceutical company that enables scientific advancement through supporting the clinical development of high-value medicines. Ligand has two primary platform technologies that are available for outlicense – Captisol and Pelican. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. For its Captisol partners, Ligand's team supplies the Captisol material needed for their programs. Ligand's Pelican Expression Technology is a robust, validated, cost-effective, and scalable platform for ecombinant protein production that is especially well-suited for complex, large-scale protein production where traditional systems are not. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.